SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

10 May 2024 Evaluate
The Revenue for the quarter ended  March 2024 of Rs. 40366.60 millions grew by 13.20 % from Rs. 35658.80 millions.The Total revenue for the quarter ended March 2024 of  Rs. 9820.30  millions  grew by 238.27% from Rs. 2903.10 millions.Operating profit surged to 13665.00 millions from the corresponding previous quarter of 8312.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 40366.60 35658.80 13.20 165743.40 143453.40 15.54 165743.40 143453.40 15.54
Other Income 5386.10 1197.10 349.93 10706.60 4567.90 134.39 10706.60 4567.90 134.39
PBIDT 13665.00 8312.00 64.40 55548.10 38096.80 45.81 55548.10 38096.80 45.81
Interest 54.50 92.70 -41.21 202.50 222.70 -9.07 202.50 222.70 -9.07
PBDT 13610.50 6360.30 113.99 55345.60 36015.10 53.67 55345.60 36015.10 53.67
Depreciation 1368.10 1615.80 -15.33 5875.90 5959.10 -1.40 5875.90 5959.10 -1.40
PBT 12242.40 4744.50 158.03 49469.70 30056.00 64.59 49469.70 30056.00 64.59
TAX 2422.10 1841.40 31.54 12327.80 8615.40 43.09 12327.80 8615.40 43.09
Deferred Tax 20.30 -385.80 -105.26 60.90 -400.90 -115.19 60.90 -400.90 -115.19
PAT 9820.30 2903.10 238.27 37141.90 21440.60 73.23 37141.90 21440.60 73.23
Equity 1614.70 1614.30 0.02 1614.70 1614.30 0.02 1614.70 1614.30 0.02
PBIDTM(%) 33.85 23.31 45.23 33.51 26.56 26.20 33.51 26.56 26.20

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×